Rinvoq — Medical Mutual

Initial criteria

• Patient age ≥ 18 years
• Patient has had a 3-month trial of at least one tumor necrosis factor inhibitor OR unable to tolerate 3-month trial
• Rinvoq is prescribed by or in consultation with a rheumatologist

Reauthorization criteria

• Patient has been established on therapy ≥ 6 months
• Patient experienced a beneficial clinical response when assessed by ≥ 1 objective measure OR patient experienced an improvement in at least one symptom such as decreased pain or stiffness, or improved function/activities of daily living

Approval duration

initial 6 months; renewal 1 year